Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
The pharmaceutical industry continues to show robust performance in Q3 2025, with key players reporting strong sales driven by oncology, immunology, and metabolic drugs. Eli Lilly maintains its lead in market capitalization, fueled by high demand for its GLP-1 treatments Mounjaro and Zepbound, with projected full-year revenue growth of around 32%. Johnson & Johnson reported Q3 sales of $24.0 billion, up 6.8%, and raised its 2025 sales outlook. Roche achieved 7% sales growth in the first nine months to CHF 45.9 billion ($52.8 billion), raising its full-year guidance to mid-single-digit growth. Other top companies like AstraZeneca, Novartis, and Vertex reported double-digit growth in key segments. Challenges persist, including patent expirations and biosimilar competition, but new approvals and acquisitions signal continued innovation. This edition updates data with Q3 2025 figures where available. Credit: fiercepharma.co...
The XRP ETF ecosystem has exploded in November 2025, with four major U.S. spot ETFs launching between November 13 and November 24, driving cumulative inflows past $1 billion since Canary's (XRPC) debut. Regulatory tailwinds from the SEC's July 2025 guidance and Ripple's $125 million settlement have fueled this surge, alongside XRP's price holding above $2.20 (currently ~$2.22, up 1.4% intraday despite broader market volatility). A fierce "fee war" has pushed U.S. spot expense ratios to historic lows (0.19–0.35%), with waivers extending through mid-2026 for many. Analysts now project $10–15 billion in total inflows over the next 12 months, as spot products capture 85%+ of flows. European and Canadian ETFs continue to thrive for regional investors, while futures-based options suit leveraged traders. On November 13, 2025, Canary Capital's Canary XRP ETF (ticker: XRPC) became the first pure-play spot XRP ETF to trade on a major U.S. exchange (Nasdaq). Its deb...
Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. The shortages are becoming impossible to ignore, and warnings from the industry are growing dire, as the voracious appetite of AI data centers begins to consume the lion's share of the world's memory and flash production capacity. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM starting to climb. The shift has its roots in the cyclical na...
Here are the top 10 pharmaceutical companies by market cap. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This 2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Source: CompaniesMarketCap.com Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects its sales to fall between $58 billion and $61 billion. Meanwhile, Novo—which also has been powered by sales...
Introduction As 2025 concludes, ETFs remain a cornerstone for diversified growth investing, navigating an AI-fueled rally, escalating defense needs from global realignments, and a Fed tilting toward measured easing amid persistent inflation. This updated guide refreshes November's top picks with December data, incorporating recent market surges in semiconductors and crypto, while addressing tariff escalations and volatility. Emphasis on blending high-growth themes like AI and defense with hedges like gold and Bitcoin ensures resilience. Diversification across sectors is key to capturing upside while buffering downturns. Top 10 ETFs Selections highlight YTD performance, AUM for dependability, and anticipated growth in AI, tech, healthcare, and broad markets. Data sourced from TradingView, Yahoo Finance, and recent analyses. Ranking Methodology YTD Performance: Based on reported or estimated returns for 2025. Higher returns rank higher, with adjustments for cr...
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Updated Status as of November 2025 The core thesis from the original article remains valid: Bitcoin continues to behave like a high-beta tech asset with a strong positive correlation to the Nasdaq 100. However, the relationship has evolved with some important nuances in 2025. 30-day rolling correlation (BTC vs. Nasdaq 100) : ~0.80 → Highest level since 2022 and the second-highest in the past decade (sources: Kobeissi Letter, Wintermute, CoinDesk) 5-year average correlation : ~0.54 → Confirms the recent spike is part of a longer-term uptrend that began in 2020 Year-to-date performance (Jan 1 – Nov 20, 2025) : → Nasdaq 100: +20% → Bitcoin: +3–4% → BTC has significantly underperformed tech stocks despite the tight correlation Key new phenomenon in 2025 : Strong negativ...
As of November 2025, gold prices have surged to new all-time highs, trading around $4,000 per ounce after rallying over 50% year-to-date amid persistent inflation, geopolitical tensions, and strong central bank demand. This has propelled gold ETFs to exceptional performance, with physical gold funds delivering 40-60% YTD returns and mining-focused ETFs often exceeding 100%. Top gold ETFs span U.S., European, and Chinese markets, providing options for physical gold exposure or leveraged mining plays. This updated overview incorporates the latest performance data, trends, and forecasts as of early November 2025, highlighting shifts since mid-year. Credit: Goldprice.org U.S. Gold ETFs U.S. gold ETFs remain dominant, with physical funds like GLD and IAU offering stability, while mining ETFs like GDX provide amplified returns amid expanding miner margins. 1. SPDR Gold MiniShares Trust (GLDM) Type : ETF Sector : Physical Gold Performance : YTD ~+51% AUM : $17.3B Reason : Cost-effective ...
As 2025 draws to a close, the technology sector remains a dominant force in global markets, propelled by accelerating advancements in artificial intelligence (AI), semiconductors, robotics, and cloud computing. The S&P 500's tech weighting exceeds 34%, while the Nasdaq-100 is even more innovation-centric. Tech and innovation ETFs continue to provide efficient, diversified access to these high-growth areas, mitigating single-stock risks while capturing upside potential. This updated guide reviews the year-end market dynamics, selection criteria, refreshed top picks (with performance through early December 2025), portfolio strategies, risks, and outlooks for 2026 and beyond. This guide explores the current market landscape, key selection criteria for ETFs, top picks for 2025, portfolio-building strategies, associated risks, and forward-looking forecasts. Whether you're a beginner investor or a seasoned portfolio manager, this resource will help you navigate the evolving world...
The semiconductor industry remains a pivotal engine of global technological advancement, powering everything from smartphones and electric vehicles to cutting-edge AI and cloud computing infrastructure. For investors seeking to gain diversified exposure to this booming sector, semiconductor and AI-themed exchange-traded funds (ETFs) have emerged as efficient vehicles. Update: Top 10 Stocks and ETFs Poised to Outperform in October 2025 A set of leading semiconductor and AI ETFs competing with VanEck Semiconductor ETF (SMH) for 2025, along with key growth projections and features, is as follows: Top Semiconductor ETFs (Competitors to SMH) VanEck Semiconductor ETF (SMH) : The largest semiconductor ETF tracking the MVIS US Listed Semiconductor 25 Index, heavily weighted toward Nvidia (20%+), TSMC, and Broadcom. It offers concentrated exposure and has a 5-year annualized return of around 29.6%. Expense ratio: 0.35%. iShares Semiconductor ETF (SOXX) : Tracks the ICE Semiconductor...
Comments